›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:FoundationOne® Heme CDx
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
RocheType:
Laboratory Developed Test
Related tests:
Evidence Level:
Resistant: C4 – Case Studies
[PAK4 deletion-Prolymphocytic Leukemia-alemtuzumab]
Source:
Title:
First reported case of BRAF V600E mutation in T-cell prolymphocytic leukaemia
Published date:
07/25/2020
Excerpt:
Subsequently, he was transitioned to alemtuzumab consolidation and completed 11 weeks of therapy with sustained haematologic response. However, progressive disease was noted with increased lymphadenopathy on positron emission tomography/computed tomography (PET‐CT) and CT scans. Left inguinal node and bone marrow biopsies confirmed disease involvement. Molecular evaluation by next generation sequencing (FoundationOne Heme panel) on the lymph node tissue demonstrated BRAF V600E, ATM D2721N, CDKN2A/B loss, RAD50 Y625, STAT5B N642H and TCL1A rearrangement.
DOI:
10.1111/bjh.16992
Evidence Level:
Resistant: C4 – Case Studies
[BRAF V600E-Prolymphocytic Leukemia-venetoclax]
Source:
Title:
First reported case of BRAF V600E mutation in T-cell prolymphocytic leukaemia
Published date:
07/25/2020
Excerpt:
Our patient, having progressed through standard of care treatments, was trialled on novel treatments including dasatinib, venetoclax and vemurafenib.
DOI:
10.1111/bjh.16992
Evidence Level:
Resistant: C4 – Case Studies
[CDKN2A deletion-Prolymphocytic Leukemia-alemtuzumab]
Source:
Title:
First reported case of BRAF V600E mutation in T-cell prolymphocytic leukaemia
Published date:
07/25/2020
Excerpt:
Subsequently, he was transitioned to alemtuzumab consolidation and completed 11 weeks of therapy with sustained haematologic response. However, progressive disease was noted with increased lymphadenopathy on positron emission tomography/computed tomography (PET‐CT) and CT scans. Left inguinal node and bone marrow biopsies confirmed disease involvement. Molecular evaluation by next generation sequencing (FoundationOne Heme panel) on the lymph node tissue demonstrated BRAF V600E, ATM D2721N, CDKN2A/B loss, RAD50 Y625, STAT5B N642H and TCL1A rearrangement.
DOI:
10.1111/bjh.16992
Evidence Level:
Resistant: C4 – Case Studies
[TCL1A rearrangement-Prolymphocytic Leukemia-alemtuzumab]
Source:
Title:
First reported case of BRAF V600E mutation in T-cell prolymphocytic leukaemia
Published date:
07/25/2020
Excerpt:
Subsequently, he was transitioned to alemtuzumab consolidation and completed 11 weeks of therapy with sustained haematologic response. However, progressive disease was noted with increased lymphadenopathy on positron emission tomography/computed tomography (PET‐CT) and CT scans. Left inguinal node and bone marrow biopsies confirmed disease involvement. Molecular evaluation by next generation sequencing (Foundation One Heme panel) on the lymph node tissue demonstrated BRAF V600E, ATM D2721N, CDKN2A/B loss, RAD50 Y625, STAT5B N642H and TCL1A rearrangement.
DOI:
10.1111/bjh.16992
Evidence Level:
Resistant: C4 – Case Studies
[STAT5B N642H-Prolymphocytic Leukemia-alemtuzumab]
Source:
Title:
First reported case of BRAF V600E mutation in T-cell prolymphocytic leukaemia
Published date:
07/25/2020
Excerpt:
Subsequently, he was transitioned to alemtuzumab consolidation and completed 11 weeks of therapy with sustained haematologic response. However, progressive disease was noted with increased lymphadenopathy on positron emission tomography/computed tomography (PET‐CT) and CT scans. Left inguinal node and bone marrow biopsies confirmed disease involvement. Molecular evaluation by next generation sequencing (Foundation One Heme panel) on the lymph node tissue demonstrated BRAF V600E, ATM D2721N, CDKN2A/B loss, RAD50 Y625, STAT5B N642H and TCL1A rearrangement.
DOI:
10.1111/bjh.16992
Evidence Level:
Resistant: C4 – Case Studies
[RAD50 Y625-Prolymphocytic Leukemia-alemtuzumab]
Source:
Title:
First reported case of BRAF V600E mutation in T-cell prolymphocytic leukaemia
Published date:
07/25/2020
Excerpt:
Subsequently, he was transitioned to alemtuzumab consolidation and completed 11 weeks of therapy with sustained haematologic response. However, progressive disease was noted with increased lymphadenopathy on positron emission tomography/computed tomography (PET‐CT) and CT scans. Left inguinal node and bone marrow biopsies confirmed disease involvement. Molecular evaluation by next generation sequencing (Foundation One Heme panel) on the lymph node tissue demonstrated BRAF V600E, ATM D2721N, CDKN2A/B loss, RAD50 Y625, STAT5B N642H and TCL1A rearrangement.
DOI:
10.1111/bjh.16992
Evidence Level:
Resistant: C4 – Case Studies
[BRAF V600E-Prolymphocytic Leukemia-dasatinib]
Source:
Title:
First reported case of BRAF V600E mutation in T-cell prolymphocytic leukaemia
Published date:
07/25/2020
Excerpt:
Our patient, having progressed through standard of care treatments, was trialled on novel treatments including dasatinib, venetoclax and vemurafenib.
DOI:
10.1111/bjh.16992
Evidence Level:
Resistant: C4 – Case Studies
[ATM D2721N-Prolymphocytic Leukemia-alemtuzumab]
Source:
Title:
First reported case of BRAF V600E mutation in T-cell prolymphocytic leukaemia
Published date:
07/25/2020
Excerpt:
Subsequently, he was transitioned to alemtuzumab consolidation and completed 11 weeks of therapy with sustained haematologic response. However, progressive disease was noted with increased lymphadenopathy on positron emission tomography/computed tomography (PET‐CT) and CT scans. Left inguinal node and bone marrow biopsies confirmed disease involvement. Molecular evaluation by next generation sequencing (Foundation One Heme panel) on the lymph node tissue demonstrated BRAF V600E, ATM D2721N, CDKN2A/B loss, RAD50 Y625, STAT5B N642H and TCL1A rearrangement.
DOI:
10.1111/bjh.16992
Evidence Level:
Resistant: C4 – Case Studies
[BRAF V600E-Prolymphocytic Leukemia-alemtuzumab]
Source:
Title:
First reported case of BRAF V600E mutation in T-cell prolymphocytic leukaemia
Published date:
07/25/2020
Excerpt:
Subsequently, he was transitioned to alemtuzumab consolidation and completed 11 weeks of therapy with sustained haematologic response. However, progressive disease was noted with increased lymphadenopathy on positron emission tomography/computed tomography (PET‐CT) and CT scans. Left inguinal node and bone marrow biopsies confirmed disease involvement. Molecular evaluation by next generation sequencing (FoundationOne Heme panel) on the lymph node tissue demonstrated BRAF V600E, ATM D2721N, CDKN2A/B loss, RAD50 Y625, STAT5B N642H and TCL1A rearrangement.
DOI:
10.1111/bjh.16992
Evidence Level:
Sensitive: C4 – Case Studies
[LMNA-NTRK1 fusion-Soft Tissue Sarcoma-larotrectinib]
Title:
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
Excerpt:
The tumor of a 41-year-old woman with soft-tissue sarcoma metastatic to the lung was found to harbor an LMNA-NTRK1 gene fusion...In a phase I study of LOXO-101 (ClinicalTrials.gov no. NCT02122913), this patient's tumors underwent rapid and substantial tumor regression, with an accompanying improvement in pulmonary dyspnea, oxygen saturation, and plasma tumor markers.
DOI:
10.1158/2159-8290.CD-15-0443
Trial ID:
